Internationale Publikationen
Hier stellen wir eine Auswahl wissenschaftlicher Veröffentlichungen zur Verfügung, die im Zusammenhang mit der IOZK-Immuntherapie stehen.
Sie können mit Hilfe der Filter eine Auswahl nach Tumorarten und Methoden treffen, oder Suchbegriffe eingeben.
Immunotherapy in lung cancer
Fighting fire with fire: the revival of thermotherapy for gliomas
Immunotherapy prospects in the treatment of lung cancer and mesothelioma
Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma
Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model
Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection
Antigen trapping by dendritic cells for antitumor therapy
Generation of multiple peptide cocktail-pulsed dendritic cells as a cancer vaccine
Immunotherapy and lung cancer: current developments and novel targeted therapies
Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function
Dendritic cell-based vaccines: clinical applications in breast cancer
Novel dendritic cell-based vaccination in late stage melanoma
Dendritic cell immunotherapy in uterine cancer
Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies
Diffuse intrinsic pontine glioma: time for therapeutic optimism
Tumor cell lysates as immunogenic sources for cancer vaccine design
Dendritic cells in cancer immunotherapy clinical trials: are we making progress?
Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go
Wilms‘ Tumor Gene 1 (WT1)–loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial